logo-loader

Medicus Pharma expects interim data from Phase 2 skin cancer trial shortly

Published: 08:40 14 Feb 2025 EST

Medicus Pharma - Medicus Pharma expects interim data from Phase 2 skin cancer trial by quarter-end

Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) has announced progress in its Phase 2 clinical study SKNJCT-003, which is evaluating its investigational drug D-MNA in basal cell carcinoma (BCC).

The company said that the trial, currently underway at nine clinical sites in the United States, has now randomized more than 50% of the 60 patients expected to be enrolled.

Medicus is on track to complete an interim data analysis before the end of the first quarter, according to a statement from Medicus.

Findings will be submitted to the United States Food and Drug Administration (FDA) seeking a Type C meeting in Q2, aiming to fast-track the clinical development of D-MNA.

The study evaluates two dose levels (100μg and 200μg) against a placebo, with the high dose previously proven safe and well-tolerated in a Phase 1 study where six participants achieved a complete response.

Investors welcomed the update, sending shares of Medicus Pharma up 5.5% to about $3.25 before Friday’s opening bell.

Medicus Pharma shares rationale as CD228V becomes lead development priority

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company's third-quarter 2026 financial results, which showed a narrower net loss and lower general and administrative expenses as Medicus shifts its development focus towards CD228V, an antibody-drug...

1 week, 2 days ago